ArticleBMC medical imaging2026
Artificial intelligence and radiomics on computed tomography for differentiating hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a multimodal integration approach.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiating between hepatocellular carcinomas (HCC) and intrahepatic cholangiocarcinomas (ICC) non-invasively is clinically critical but challenging, impacting patient management. This study aims to employ contrast-enhanced computed tomography (CECT) radiomics and artificial intelligence to distinguish HCC from ICC.
methodsThis retrospective study (October 2014–July 2024) included 186 patients with pathologically confirmed HCC (n = 111) or ICC (n = 75) from two centers. A total of 134 patients from Center A were randomly divided into a training cohort (n = 93) and an internal validation cohort (n = 41), while 52 patients from Center B were assigned to an external validation cohort. For each patient, 4,520 radiomic features were extracted from the volume of interest. After feature reproducibility assessment, stable features were selected to construct the radiomics-based model. Logistic regression analysis was used to identify independent clinical predictors. A dataset comprising region of interest images per patient was analyzed using multiple neural network architectures. Outputs from the radiomics, clinical, and deep learning branches were fused via the fusion neural network to create the final model.
resultsLogistic regression identified two independent clinical predictors: cirrhosis status and elevated carbohydrate antigen 19–9. In radiomics-based module, the support vector machine model based on features from four CECT phases achieved an area under the curve (AUC) of 0.96 in a single internal validation assessment. In the neural network module, the self-designed hybrid neural network reached an AUC of 0.92 in the internal validation set. The fusion neural network achieved an AUC of 0.99 in the internal validation set and an AUC of 0.95 in the external validation set, outperforming the single-modality model.
conclusionsThe fusion neural network shows potential in distinguishing HCC from ICC and may support early individualized treatment planning. Further validation with automated segmentation and explainable tools is warranted to confirm broader generalizability and facilitate clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.